Furui Shares: 19. Furui Shares: Internal reporting system for major information (draft)
Inner Mongolia Furui Medical Technology Co., Ltd. Internal reporting system for major information Inner Mongolia Furui Medical Technology Co., Ltd.
Internal reporting system for major information (draft)
(Applicable after H shares are issued and listed)
Chapter 1 General Provisions
Article 1 In order to standardize the internal reporting of major information of Inner Mongolia Furui Medical Technology Co., Ltd. (hereinafter referred to as the "Company"), ensure the rapid transmission, collection and effective management of major information within the company, disclose information in a timely, accurate, comprehensive and complete manner, and safeguard the legitimate rights and interests of investors, in accordance with the "Company Law of the People's Republic of China" and the Securities Law of the People's Republic of China "Measures for the Administration of Information Disclosure by Listed Companies", "Shenzhen Stock Exchange GEM Stock Listing Rules (Revised in 2025)", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 4 - GEM Industry Information Disclosure", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - GEM Listing" This system is formulated based on the actual situation of the company, including the "Standardized Operation of the Company (Revised in 2025)", the "Securities Listing Rules of The Stock Exchange of Hong Kong Limited" (hereinafter referred to as the "Hong Kong Listing Rules"), and the "Articles of Association of Inner Mongolia Furui Medical Technology Co., Ltd." (hereinafter referred to as the "Articles of Association").
Article 2 The company's internal reporting system for major information refers to a system that when a situation or event occurs, occurs, or is about to occur that may have or has had a greater impact on the company's stock and its derivatives trading prices or investment decisions, units, departments, and personnel with reporting obligations in accordance with the provisions of this system shall report the relevant information to the company's responsible leaders and the secretary of the board of directors as soon as possible.
Article 3 This system applies to all departments, subsidiaries and joint-stock companies of the company.
Chapter 2 Obligors of major information reporting
Article 4 The reporting obligors referred to in this system are:
(1) Directors and senior managers of the company;
(2) The heads of various departments and subsidiaries of the company;
Inner Mongolia Furui Medical Technology Co., Ltd. Internal reporting system for major information
(3) The company’s directors, supervisors and senior managers assigned to each joint-stock company;
(4) The company’s controlling shareholders, actual controllers, and other shareholders holding more than 5% of the company’s shares;
(5) Other persons who have reporting obligations according to the regulations of the securities regulatory authorities and stock exchanges where the company's shares are listed.
Article 5 The company’s board of directors is responsible for managing the company’s major information and its disclosure.
Article 6 The office of the company's board of directors is the daily office of the board of directors, led by the secretary of the board of directors, and specifically implements the management and disclosure of major information.
Article 7 The reporting obligor is the first person responsible for internal reporting of major information, and has the obligation to urge the department or unit to collect and organize information, and to report to the board of directors office the major information known within the scope of its authority. The reporting obligor is responsible for the authenticity, accuracy and completeness of the reported information and materials, and may designate specialized personnel to serve as the liaison for internal reporting of major information and cooperate with the board of directors office to complete various information disclosure matters.
Article 8 When the situation or event described in Chapter 3 of this system occurs, occurs or is about to occur, the person with the reporting obligation shall perform the reporting obligation in a timely manner upon learning of the relevant information.
Article 9 The reporting obligor and other insiders have the obligation to keep confidential the important information before it is publicly disclosed.
Chapter 3 Scope of Significant Information
Article 10 Significant information includes but is not limited to the following content and information formed by its continuous change process:
(1) Meeting matters: The company holds a general manager office meeting, and each subsidiary holds a shareholder meeting, board of directors meeting, and board of supervisors meeting. The content of the meeting (meeting resolutions or meeting minutes) should be reported after the meeting;
(2) Transaction matters, including:
Purchase or sell assets;
External investment (including entrusted financial management, investment in subsidiaries, etc., excluding the establishment or capital increase of wholly-owned subsidiaries);
Provide financial assistance (including entrusted loans);
Inner Mongolia Furui Medical Technology Co., Ltd. Internal reporting system for major information 4. Providing guarantees (referring to the guarantees provided by the company to others and guarantees to its holding subsidiaries);
Lease or lease assets;
Sign management contracts (including entrusted operation, entrusted operation, etc.);
Donate or receive donated assets;
Creditor's rights or debt restructuring;
Transfer of research and development projects;
Sign a license agreement;
Waiver of rights (including waiving the right of first refusal, the right to first subscribe for capital contribution, etc.);
Asset mortgage and application for bank credit;
Other transactions identified by the stock exchange where the company's shares are listed, including but not limited to transactions involving Chapter 14 and Chapter 14A of the Hong Kong Listing Rules.
The following activities of the company are not included in the matters specified in the preceding paragraph: the purchase of raw materials, fuel and power related to daily operations, and the sale of products, commodities and other assets related to daily operations. However, if the asset replacement involves the purchase or sale of such assets, although the transactions specified in the previous paragraph are carried out, they are the main business activities of the company and are still included in the provisions of the previous paragraph.
Among the above-mentioned transactions, when a transaction occurs in item 2 or 4, the reporting obligor must perform reporting obligations regardless of the amount; when transactions in the remaining items listed in the items meet one of the following standards, the reporting obligor shall perform reporting obligations:
The total assets involved in the transaction account for more than 10% of the company's latest audited total assets. If the total assets involved in the transaction have both book value and appraisal value, the higher one will be used as the calculation data;
The net assets involved in the transaction target (such as equity) account for more than 10% of the company's latest audited net assets, and the absolute amount exceeds 10 million yuan. If the net assets involved in the transaction have both book value and appraisal value, the higher one will be used as the calculation data;
Inner Mongolia Furui Medical Technology Co., Ltd. Important information internal reporting system 3. The main business income related to the transaction target (such as equity) in the most recent fiscal year accounts for more than 10% of the company's audited main business income in the most recent fiscal year, and the absolute amount exceeds 10 million yuan;
The net profit related to the transaction object (such as equity) in the most recent fiscal year accounts for more than 10% of the company's audited net profit in the most recent fiscal year, and the absolute amount exceeds 1 million yuan;
The transaction amount (including debts and expenses assumed) accounts for more than 10% of the company's latest audited net assets, and the absolute amount exceeds 10 million yuan;
The profit generated from the transaction accounts for more than 10% of the company's audited net profit in the most recent fiscal year, and the absolute amount exceeds 1 million yuan.
If the data involved in the calculation of the above indicators is negative, its absolute value will be used for calculation.
If the subject matter of the transaction is equity, and the purchase or sale of the equity will result in a change in the scope of the listed company's consolidated statements, the equity corresponds to all the company's assets and operating income as the calculation standard, and the aforementioned provisions shall apply. If the aforementioned equity transactions do not result in a change in the scope of the consolidated statements, the relevant financial indicators shall be calculated based on the proportion of changes in the company's equity holdings, and the aforementioned provisions shall apply.
(3) Related transactions:
Related transactions refer to the transfer of resources or obligations between a company or its holding subsidiary and its related parties, including: 1. Transactions specified in Item (2) of Article 10;
Purchase raw materials, fuel, and power;
Selling products and merchandise;
Provide or accept labor services;
Entrust or entrust sales;
Joint investment by related parties;
Other matters that may result in the transfer of resources or obligations through agreement.
Inner Mongolia Furui Medical Technology Co., Ltd. Important Information Internal Reporting System Related parties of the company include related legal persons and related natural persons. The identification criteria for related parties shall be in accordance with the relevant provisions of the securities listing rules of the place where the company's shares are listed. If the company provides guarantees to related parties, it should report them in a timely manner regardless of the amount. If related-party transactions occur that meet the following standards, they must be reported in a timely manner:
Transactions with related natural persons with a transaction amount exceeding 300,000 yuan;
The transaction amount with related legal persons exceeds 3 million yuan, and accounts for more than 0.5% of the absolute value of the company's latest audited net assets;
Connected transactions under the Hong Kong Listing Rules.
(4) If any major litigation or arbitration matter that occurs in the company falls into one of the following circumstances, the relevant information shall be reported in a timely manner: 1. The amount involved accounts for more than 10% of the absolute value of the company's latest audited net assets, and the absolute amount exceeds 10 million yuan; 2. The resolution involving the company's shareholders' meeting or board of directors is applied for cancellation or declared invalid;
May have a greater impact on the company's production and operation, stability of control, trading prices of the company's stocks and their derivatives, or investment decisions;
Other circumstances considered necessary by the stock exchange where the company's shares are listed.
The company shall promptly report the significant progress of major litigation and arbitration matters and their impact on the company, including but not limited to the results of the first and second instance of litigation cases, the results of arbitration awards, and the execution of judgments and awards, etc. If the company's litigation or arbitration matters occur within twelve consecutive months and the cumulative amount involved reaches the standard mentioned in the preceding paragraph, this provision shall apply.
(5) Other major events:
Change the investment project of raised funds;
Substantial changes in performance (more than 50%), performance forecasts and revisions to performance forecasts;
Profit distribution and conversion of capital reserve funds into share capital;
Abnormal stock trading fluctuations and clarification matters;
Inner Mongolia Furui Medical Technology Co., Ltd. Internal reporting system for major information 5. Major matters involved in convertible corporate bonds;
The company and its shareholders have commitments;
A major loss occurs or a major loss exceeding 10% of the net assets at the end of the previous year;
Major debts have occurred, major debts have not been paid when due, or major claims have not been paid when due;
May be legally liable for major breach of contract or large compensation;
Provision for large asset impairment;
Major lawsuits and arbitrations involving the company, resolutions of shareholders’ meetings and board of directors are revoked or declared invalid in accordance with the law;
The company decides to dissolve or has its business license revoked by the competent authority according to law, ordered to close down, or forced to dissolve;
The company is expected to have negative net assets;
The main debtor becomes insolvent or enters bankruptcy proceedings, and the company does not withdraw sufficient bad debt provisions for the corresponding claims; 15. The company purchases or sells major assets within one year for more than 30% of the company's total assets, or the company's main assets for business use are seized, seized, frozen, mortgaged, pledged, sold or scrapped for more than 30% of the assets at one time;
Main or all business has come to a standstill;
The company is investigated by the competent authorities for suspected violations of laws and regulations, or is subject to major administrative or criminal penalties. The controlling shareholders, actual controllers, directors and senior managers are investigated by competent authorities for suspected serious violations of laws and regulations, take compulsory measures, or are subject to major administrative or criminal penalties;
There are changes in the company's directors or managers, and the chairman or managers are unable to perform their duties or are investigated by the competent authorities for suspected violations of laws and disciplines, take compulsory measures, or receive major administrative or criminal penalties;
The company's core technical team or key technical personnel and other personnel who have a significant impact on the company's core competitiveness resign or undergo major changes;
The company’s core trademarks, patents, proprietary technologies, franchise rights and other important assets or core technologies currently in use are licensed to Inner Mongolia Furui Medical Technology Co., Ltd. During the period of the internal reporting system for major information, major disputes arise, use is restricted, or other major adverse changes occur;
Main products, core technologies, key equipment, business models, etc. face the risk of being replaced or eliminated;
The research and development of important R&D projects fails, is terminated, or is not approved by relevant departments, or the company gives up its continued investment in or control of important core technology projects;
Major environmental, production and product safety accidents occur;
Receive notification of the government department’s decision to rectify, stop production, relocate, or close within a time limit;
Improper use of science and technology and violation of scientific ethics;
The company independently or in cooperation with a third party researches and develops new technologies, new products, new businesses, new services, or transforms existing technologies, and the relevant matters have a significant impact on the company's profits or future development;
Other events determined by the stock exchange where the company's shares are listed or the company.
If the above matters involve specific amounts, the provisions of Article 10 of these Rules shall apply mutatis mutandis.
(6) Major changes:
Change the company name, securities abbreviation, company articles of association, registered capital, registered address, main office address, contact number, etc. If the company articles of association change, the new company articles of association shall also be disclosed in qualified media;
There are major changes in the business policy and business scope or the company's main business;
Change accounting policies or accounting estimates;
The board of directors adopts the issuance of new shares or other domestic and overseas issuance and financing plans;
The company receives corresponding review opinions on the issuance of new shares or other domestic and overseas issuance and financing applications, or major asset restructuring matters; 6. The shareholding situation of shareholders or actual controllers holding more than 5% of the company's shares or the situation of controlling the company has occurred or is expected to undergo major changes;
The situation in which shareholders or actual controllers holding more than 5% of the company's shares hold shares or control the company has changed significantly. Inner Mongolia Furui Medical Technology Co., Ltd. has institutionalized internal reporting of major information, and the company's actual controller and other companies it controls engage in the same or similar business as the company have changed significantly;
The company’s director, general manager, board secretary or financial officer resigns or is dismissed by the company;
Major changes in production and operation conditions, external conditions or production environment (including major changes in main product prices or market capacity, raw material procurement, sales methods, important suppliers or customers, etc.);
Entering into important contracts may have a significant impact on the company's assets, liabilities, equity or operating results;
Changes in the external macro-environment such as laws, administrative regulations, departmental rules, normative documents, policies, market environment, trade conditions, etc. may have a significant impact on the company's operations;
Appoint or dismiss the accounting firm that audits the company;
The court ruled that the controlling shareholder is prohibited from transferring its shares;
More than 5% of the company's shares held by any shareholder are pledged, frozen, judicially auctioned, placed in custody, set up as a trust, or have voting rights restricted in accordance with the law;
Obtain additional benefits such as large government subsidies;
Other events that may have a significant impact on the company's assets, liabilities, equity or operating results occur;
Other circumstances determined by the securities regulatory authorities and stock exchanges where the company's shares are listed or by the company.
(7) If the company signs a one-time purchase, sales, project contracting or labor service contract related to daily production and operation, and the amount accounts for more than 50% of the company's audited main business income or total assets in the most recent fiscal year, and the absolute amount exceeds 100 million yuan, it must be reported in a timely manner;
The company shall timely disclose the progress of major contracts, including but not limited to the entry into force of the contract, major changes or major uncertainties in the performance of the contract, early termination of the contract, termination of the contract, etc.
(8) Industry information
Inner Mongolia Furui Medical Technology Co., Ltd. Important Information Internal Reporting System 1. During the first registration or change of registration process for important products in Class II and Class III medical devices stipulated in the "Regulations on Supervision and Administration of Medical Devices", if any of the following circumstances occurs, the company shall report in a timely manner:
(1) Clinical trials can be carried out or completed in accordance with relevant regulations;
(2) If the reported medical device registration application is terminated;
(3) Enter the innovative medical device approval process;
(4) Being ordered to return the registration application during the review process;
(5) Obtain a medical device registration certificate or medical device production license;
(6) The sales volume in the most recent fiscal year accounts for more than 10% of the company's main business revenue in the same period, or the contents of the medical device registration certificate or medical device production license of the top ten products by sales have changed;
(7) The stock exchange where the company's shares are listed or other circumstances that the company believes may have a significant impact on the company's medical device research and development and registration.
When a company obtains a medical device registration certificate or enters the registration process through other means other than self-research and development, it should report it in a timely manner.
When companies register medical devices in the United States or the European Union, they should make timely disclosures with reference to domestic registration procedures. 4. The company's report on the matters specified in items 1-3 of Article 10 (8) of this system shall include the following: (1) Basic information of the medical device, including the name of the medical device, registration classification, clinical use, etc.; (2) The current registration and approval stage of the medical device, and the subsequent required approval process; (3) Market conditions of similar medical devices (such as the current research status, production, sales and use of similar medical devices at home and abroad, etc.);
(4) The main risks existing in the development and registration process of the medical device;
(5) The stock exchange where the company’s shares are listed or other content that the company deems necessary to explain.
Inner Mongolia Furui Medical Technology Co., Ltd. Internal Reporting System for Important Information 5. If any of the following circumstances occurs, it shall be disclosed in a timely manner and the impact on the company shall be explained:
(1) The sales of the company in the most recent fiscal year accounted for more than 10% of the company's main business revenue in the same period, or the medical device registration certificate of the top ten products by sales has expired before the company decided not to apply for renewal, and was revoked, canceled or expired; (2) The sales revenue of the company in the most recent fiscal year accounted for more than 30% of the company's sales revenue in the most recent fiscal year, or the average sales price of the top five products by sales has dropped significantly, and the decline rate is more than 30% compared with the beginning of the year;
(3) Major medical accidents or product quality problems occur in the company's main products. Due to quality problems, product sampling fails, product recalls falling within the first and second levels stipulated in the "Medical Device Recall Management Measures" occur, and a wide range of media questions and safety complaints occur;
(4) There are major changes in industry policies, major patent infringement lawsuits are filed against the company's main products, and new products or technical routes appear on the market and have a major adverse impact on the company;
(5) The stock exchange where the company's shares are listed or other circumstances that the company considers to have a significant impact on the company's production and operations. 6. If the medical device produced and sold by the company wins the bid and enters the centralized volume purchasing catalog, the following information shall be reported in a timely manner: (1) Basic information of the product, including product name, registration classification, and clinical use;
(2) The product’s sales volume in the most recent fiscal year and its proportion to the company’s main business income in the same period;
(3) The product is included in the winning bid price, procurement quantity and procurement area of the centralized volume procurement catalog;
(4) The impact on the company of this product being included in the centralized volume purchasing catalog.
If a company fails to win the bid for centralized bulk procurement of products produced and sold, it shall report promptly after the relevant bid winning results are announced. 7. During the drug R&D and registration process, if any of the following circumstances occurs during the drug R&D and registration process, the company shall report any of the following situations:
Inner Mongolia Furui Medical Technology Co., Ltd. Internal reporting system for major information (1) Clinical trials can be carried out in accordance with relevant regulations;
(2) Clinical trials have made phased progress (entering phases I, II, III and IV);
(3) Terminate clinical trials;
(4) Receive a new drug certificate;
(5) Receive drug production license approval documents (including "Drug Registration Certificate", "Imported Drug Registration Certificate", "Pharmaceutical Product Registration Certificate", etc.);
(6) Obtain a drug production license;
(7) The product passed or failed the consistency evaluation;
(8) The stock exchange where the company's shares are listed or other circumstances that the company believes may have a significant impact on the company's drug research and development and registration.
- The matters specified in the preceding paragraph shall include the following contents:
(1) Basic information of the drug, including drug name or code, registration classification, indications or functional indications; (2) The current approval stage of the drug registration, and the subsequent required approval process;
(3) Market competition and potential competition among similar drugs;
(4) The main risks existing in the drug development and registration process;
(5) The stock exchange where the company’s shares are listed or other content that the company deems necessary to explain.
Companies registering relevant drugs in the United States or the European Union should make timely disclosures with reference to domestic registration procedures.
Companies that obtain domestic and overseas clinical trial licenses, new drug certificates, drug production license approvals and other qualification documents through other channels other than self-research and development shall disclose them in a timely manner.
During the drug development and registration process, if the company completes clinical trials and obtains a clinical trial summary report, it should issue an indicative announcement. In addition to reporting the contents of Inner Mongolia Furui Medical Technology Co., Ltd.'s major information internal reporting system as specified in Item 8 of Article 10 (8) of this system, the indicative announcement of the clinical trial summary report should also report conclusive opinions on the efficacy, safety, and relationship between risks and benefits of the experimental drugs.
If the company proposes to withdraw its application for drug registration, it shall report it promptly after receiving the approval document from the competent department regarding the withdrawal of drug registration. In addition to reporting the content specified in Item 8 of Article 10 (8) of this system, the reasons for withdrawing the registration application and the impact on the company must also be reported.
If the company encounters any of the following circumstances, it shall report it promptly:
(1) The company decides not to apply for re-registration, is canceled or refuses to re-register before the expiration of the validity period of the drug production license approval document whose sales in the most recent fiscal year accounted for more than 10% of the company's main business revenue in the same period;
(2) The average sales price of products accounting for more than 30% of the company's sales revenue in the most recent fiscal year has dropped significantly, and the decline has exceeded 30% from the beginning of the year;
(3) There is a significant change in the applicable scope of drugs whose sales in the most recent fiscal year account for more than 10% of the company’s main business revenue in the same period;
(4) The competent department reaches a conclusive opinion of unqualification in the company's GMP (Good Manufacturing Practice) inspection, and the product sampling fails due to quality problems, resulting in a product recall falling within the first and second levels stipulated in the "Measures for the Administration of Drug Recalls";
(5) Group adverse reactions occur when using the company’s products or there are widespread media questions or safety complaints;
(6) The company’s drugs enter or exit the national “Medical Insurance Drug Catalog”;
(7) There are major changes in industry policies, major patent infringement lawsuits are filed against the company's main products, and new products or technical routes appear on the market, which have a major adverse impact on the company;
(8) The stock exchange where the company's shares are listed or other circumstances that the company considers to have a significant impact on the company's production and operations. 14. If a company wins the bid for a drug produced and sold by the company and enters the centralized drug procurement catalog, it shall report the following information in a timely manner:
Inner Mongolia Furui Medical Technology Co., Ltd. Important Information Internal Reporting System (1) Basic information of the drug, including drug name or code, registration classification, indications or functional indications; (2) Sales volume of the drug in the most recent fiscal year and its proportion to the company’s main business income in the same period;
(3) The drug is included in the winning bid price, purchasing quantity and purchasing area of the drug centralized bulk purchasing catalog;
(4) The impact on the company of the drug being included in the centralized drug procurement catalog.
If a company produces and sells drugs that have not won the bid and purchases them in bulk, it should promptly report and explain the impact on the company after the relevant bid winning results are announced.
Article 11 If the company's controlling shareholder or actual controller changes or is expected to change, the company's controlling shareholder shall promptly report the information to the company's chairman and board secretary after reaching an intention on the matter, and continue to report the progress of the change. If a court rules to prohibit the company's controlling shareholder from transferring the company's shares, the company's controlling shareholder should promptly report the information to the company's chairman and board secretary after receiving the court's ruling.
Chapter 4 Internal reporting procedures and management of major information
Article 12 The company implements a real-time reporting system for major information. The reporting obligor shall report to the company's board secretary in person or by telephone as soon as possible after becoming aware of the internal material information described in this system, and promptly submit or fax written documents related to the material information directly to the company's board secretary, and the originals shall be delivered when necessary.
Article 13 In accordance with the provisions of this system, relevant materials of major information shall be submitted in written form, including but not limited to: 1. The reasons for the occurrence of important events, the basic situation of all parties, the content of important matters, the impact on the company's operations, etc.;
Involved agreements, letters of intent, agreements, contracts, etc.;
Involved government approvals, laws, regulations, court judgments and situation introductions, etc.;
Opinions issued by intermediaries on important matters;
The company’s internal opinions on the approval of major matters.
Article 14 The secretary of the board of directors shall comply with relevant laws and regulations, the securities listing rules of the place where the company’s shares are listed, and other normative documents.
Inner Mongolia Furui Medical Technology Co., Ltd. stipulates the internal reporting system for major information and the relevant provisions of the "Articles of Association" to analyze and judge the reported major information. If it is necessary to perform review procedures or information disclosure obligations, the secretary of the board of directors should immediately report to the company's board of directors and audit committee, request the company's board of directors and audit committee to perform corresponding procedures, and make public disclosures in accordance with relevant regulations.
Article 15 For matters that are of concern to investors and for which information disclosure is not mandatory, the secretary of the board of directors shall promptly disclose relevant information to investors in accordance with the company's information disclosure procedures based on the actual situation, or organize relevant parties of the company to communicate with investors in a timely manner.
Chapter 5 Management and Responsibility for Internal Reporting of Major Information
Article 16 The company's internal information reporting obligor shall ensure that the information is timely, true, accurate, complete, and free of false or misleading statements or major omissions.
Article 17 All departments, subsidiaries and joint-stock companies of the company shall formulate corresponding internal information reporting systems based on actual conditions, and may designate personnel who are familiar with relevant business and regulations as information reporting liaisons, responsible for the collection and arrangement of major information of the department or the company and liaison with the company's board of directors secretary.
Article 18 Major information submission materials must be signed by the obligor before they can be submitted to the secretary of the board of directors.
Article 19 The person responsible for reporting major information has the responsibility of good faith and should always urge all departments of the company, all subordinate branches, company-controlled and joint-stock companies to collect, organize and report major information.
Article 20 The Office of the Board of Directors shall establish internal reporting files on major information, organize and properly preserve the reported information.
Article 21 If the reporting obligor fails to perform reporting obligations in accordance with the provisions of this system, resulting in violations of the company's information disclosure and causing adverse effects or losses to the company, the company will hold the reporting obligor and relevant personnel accountable. If this results in violations of information disclosure, the relevant personnel with reporting obligations shall bear the responsibility; if it causes serious impact or loss to the company, leading to errors in the company's information disclosure work and information leakage, and is punished by regulatory authorities and exchanges, the parties concerned shall be held accountable and corresponding penalties shall be imposed.
Improper performance of reporting obligations stipulated in the preceding paragraph includes the following situations:
Inner Mongolia Furui Medical Technology Co., Ltd. Internal reporting system for major information
(1) Failure to report major information or provide relevant materials;
(2) Failure to report major information or provide relevant materials in a timely manner;
(3) There are major omissions, false statements or major misunderstandings in the reported information or provided materials due to intention or gross negligence;
(4) Other situations in which reporting obligations are improperly performed.
Article 22 Once inside information is leaked, the secretary of the board of directors shall be responsible for taking timely remedial measures and making announcements, explanations and clarifications, and reporting to the stock exchange where the company's shares are listed and the Inner Mongolia Securities Regulatory Bureau.
Chapter 6 Supplementary Provisions
Article 23 Matters not covered by this system shall be implemented in accordance with the relevant provisions of relevant national laws, administrative regulations and normative documents.
Article 24 The company’s board of directors is responsible for the interpretation and revision of this system. The meaning of "related transactions" in this system includes "related transactions" as defined in the Hong Kong Listing Rules; "related parties" and "related persons" include "related persons" as defined in the Hong Kong Listing Rules; "related relationships" include "related relationships" as defined in the Hong Kong Listing Rules.
Article 25 This system shall take effect and be implemented upon review and approval by the company's board of directors and on the date when the overseas listed shares (H shares) issued by the company are listed on the main board of The Stock Exchange of Hong Kong Limited.
Inner Mongolia Furui Medical Technology Co., Ltd.
2025【】month